Morepen Laboratories Limited — Updates, 11-04-2025: Press Release

Morepen Laboratories Ltd. has unveiled an ambitious expansion plan, targeting the addition of over 1,000 medical representatives to its salesforce over the next three years, with more than 200 expected to be onboarded in FY26. This initiative aims to strengthen its formula business and enhance market penetration, aligning with India's vision for accessible healthcare. Currently, the company's formulation business is valued at approximately ₹325 crore, with an objective to reach ₹1,000 crore within five years, supported by a broadened representative network and competitive pricing on new products.

With the Indian pharmaceutical market projected to hit $130 billion by 2030, Morepen is well-positioned for growth, leveraging robust manufacturing capabilities and a strong product portfolio, including leadership in APIs. This strategic move is expected to yield higher gross margins and better returns for stakeholders, reinforcing the company's commitment to India's healthcare landscape. Investors should view this as a positive development, with potential for significant growth ahead.